Search

Savara Inc

Abrir

SetorSaúde

5.51 4.16

Visão Geral

Variação de preço das ações

24h

Atual

Mín

5.17

Máximo

5.35

Indicadores-chave

By Trading Economics

Rendimento

-5M

-37M

Funcionários

70

EBITDA

-3.8M

-37M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+111.55% upside

Dividendos

By Acuity

Próximos Ganhos

12 de ago. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

64M

1.1B

Abertura anterior

1.35

Fecho anterior

5.51

Sentimento de Notícias

By Acuity

50%

50%

158 / 340 Ranking em Healthcare

Savara Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

29 de jul. de 2026, 19:47 UTC

Savara Inc's shares are lower, marking five consecutive sessions of decline. Broader market performance is mixed as traders await the Federal Reserve's interest rate decision.

28 de jul. de 2026, 19:16 UTC

Savara Inc. shares are lower today amid ongoing price weakness. Broader markets like the FTSE 100 and DAX are showing resilience despite this decline.

27 de jul. de 2026, 14:02 UTC

Savara Inc shares are higher during Monday's session, reaching their peak at 9:30 AM ET. No specific news was identified to explain the movement.

24 de jul. de 2026, 20:02 UTC

Savara Inc shares are lower today, continuing a decline since Thursday amid high market volume. Broader market sentiment is affected by recent oil price volatility.

21 de jul. de 2026, 17:41 UTC

Savara Inc. shares are advancing today amid strong trading volume. The broader market is also positive, led by gains in technology stocks.

20 de jul. de 2026, 20:06 UTC

Savara Inc shares are higher, continuing their advance from Friday's close. Broader market sentiment remains mixed amid ongoing geopolitical concerns.

Comparação entre Pares

Variação de preço

Savara Inc Previsão

Preço-alvo

By TipRanks

111.55% parte superior

Previsão para 12 meses

Média 11.17 USD  111.55%

Máximo 16 USD

Mínimo 9 USD

Com base em 6 analistas de Wall Street que oferecem metas de preço de 12 meses para Savara Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

6 ratings

6

Comprar

0

Manter

0

Vender

Sentimento

By Acuity

158 / 340 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Savara Inc

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Langhorne, Pennsylvania.
help-icon Live chat